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Objective: The rate of complete resection (50%) and the 5-year survival
(30%) for non–small cell lung carcinomas of the superior sulcus have not
changed for 40 years. Recently, combined modality therapy has improved
outcome in other subsets of locally advanced non–small cell lung carcinoma.
This trial tested the feasibility of induction chemoradiation and surgical
resection in non–small cell lung carcinoma of the superior sulcus with the
ultimate aim of improving resectability and survival.
Methods: Patients with mediastinoscopy-negative T3-4 N0-1 superior sulcus
non–small cell lung carcinoma received 2 cycles of cisplatin and etoposide
chemotherapy concurrent with 45 Gy of radiation. Patients with stable or
responding disease underwent thoracotomy 3 to 5 weeks later. All patients
received 2 more cycles of chemotherapy and were followed up by serial
radiographs and scans. Survival was calculated by the Kaplan-Meier method
and prognostic factors were assessed for significance by Cox regression
analysis.
Results: From April 1995 to September 1999, 111 eligible patients (77 men,
34 women) were entered in the study, including 80 (72.1%) with T3 and 31
with T4 tumors. Induction therapy was completed as planned in 102 (92%)
patients. There were 3 treatment-related deaths (2.7%). Cytopenia was the
main grade 3 to 4 toxicity. Of 95 patients eligible for surgery, 83 underwent
thoracotomy, 2 (2.4%) died postoperatively, and 76 (92%) had a complete
resection. Fifty-four (65%) thoracotomy specimens showed either a patho-
logic complete response or minimal microscopic disease. The 2-year sur-
vival was 55% for all eligible patients and 70% for patients who had a com-
plete resection. To date, survival is not significantly influenced by patient
sex, T status, or pathologic response.
Conclusions: (1) This combined modality treatment is feasible in a multi-
institutional setting; (2) the pathologic complete response rates were high;
and (3) resectability and overall survival were improved compared with his-
torical experience, especially for T4 tumors, which usually have a grim prog-
nosis. (J Thorac Cardiovasc Surg 2001;121:472-83)
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Tumors of the superior sulcus are an uncommon sub-set of non–small cell lung carcinomas (NSCLCs),
which are particularly challenging to treat because they
frequently involve the brachial plexus, subclavian ves-
sels, or spine. Initially described by Henry Pancoast in
1932, NSCLC of the superior sulcus was considered
incurable until 1956, when Chardack and MacCallum1
reported the case of a patient who survived long term
after surgical resection and postoperative radiation.
Subsequently, Shaw,2 Paulson,3 and their associates
found that preoperative radiation facilitated surgical
resection and that this approach to treatment was asso-
ciated with a 30% survival at 5 years. This experience
has subsequently been confirmed by multiple small
surgical series.3-16 A recent review of 225 patients oper-
ated on from 1974 to 1998 for superior sulcus tumors
at Memorial Sloan-Kettering Cancer Center, the largest
surgical series to date, indicated that actuarial survival
at 5 years was 46% for stage IIB, 0% for stage IIIA, and
13% for stage IIIB tumors. Survival was influenced by
T and N status and completeness of resection.
However, resection was considered pathologically
complete in only 64% of T3 N0 and 39% of T4 N0
tumors.17 Locoregional disease was the most common
form of relapse.
These results emphasize the need for improved ther-
apy for NSCLC of the superior sulcus. The success of
combined modality therapy for stage IIIA (N2) NSCLC
has prompted interest in using induction chemotherapy
or chemoradiation for NSCLC of the superior sulcus. A
small single-institution phase II trial using induction
chemotherapy followed by chemoradiation and then
surgical resection reported high response, resectability,
and survival rates but also a 16.6% rate of treatment-
related deaths.15 In a previous large multi-institutional
phase II trial, the Southwest Oncology Group showed
that induction cisplatin, etoposide, and concurrent radi-
ation followed by surgical resection was a well-tolerat-
ed and effective treatment for stage IIIA (N2) and
selected IIIB NSCLC.18,19 These results led us to test
the same approach in superior sulcus tumors that did
not have mediastinal nodal metastases, a situation ide-
ally suited to the use of a concurrent induction regimen
of chemotherapy and radiation. We now report the ini-
tial results of this phase II intergroup trial coordinated
by the Southwest Oncology Group (SWOG).
Methods
Eligibility criteria. Patients were eligible for this study if
they had pathologically proven and previously untreated
NSCLC involving the superior sulcus with either a T3 or T4
primary tumor. This included patients who had (1) an apical
tumor associated with the Pancoast syndrome with or without
involvement of the chest wall or vertebral body or (2) superi-
or sulcus tumors with invasion of the chest wall, spine, or
subclavian vessels on computed tomographic (CT) or mag-
netic resonance (MR) scan with or without an associated
Pancoast syndrome. Patients with 2 or more parenchymal
lesions in the same lung were considered ineligible.
Mediastinoscopy was required in all patients, and patients
with mediastinal or supraclavicular nodal involvement (N2 or
N3 disease) were not eligible for the trial. CT scans of the
upper part of the abdomen through the adrenal glands, CT or
MR scan of the brain, and bone scan were required to exclude
the presence of distant metastatic disease. MR scan of the
thoracic spine and brachial plexus was strongly recommend-
ed to assess the extent of the primary tumor. A SWOG per-
formance status of 0 to 2 was required, and patients had to
have adequate cardiopulmonary, renal, and neurologic func-
tion to tolerate the planned chemotherapy, radiation, and sur-
gical resection. All patients were jointly evaluated before
entry into the study by a medical oncologist, a radiation
oncologist, and a thoracic surgeon. Patients were stratified by
T3 versus T4 tumor status at study entry.
Induction therapy regimen. The induction chemotherapy
and radiation began within 24 hours of each other. The
chemotherapy regimen consisted of cisplatin 50 mg/m2 on days
1, 8, 29, and 36 and etoposide 50 mg/m2 on days 1 to 5 and 29
to 33, both administered intravenously. Standard prehydration
and antiemetic medications were used. The total dose of radia-
tion was 45 Gy administered at 180 cGy per day, 5 days a week,
over a period of 5 weeks. The radiation target was defined by
CT scan and included the primary tumor and ipsilateral supra-
clavicular region, but not the mediastinum or hilum.
The toxicities for both the induction treatment and boost
chemotherapy were recorded according to the National
Cancer Institute Common Toxicity Criteria.
Evaluation after induction therapy and guidelines for
surgical resection. Two to 4 weeks after completion of the
induction therapy, patients were reassessed by history and
physical examination, repeat pulmonary function tests, and
CT scans of the chest, upper part of the abdomen, and brain.
A repeat bone scan was done if the patient had new bone pain
or elevation in the levels of alkaline phosphatase or lactic
dehydrogenase. Patients who had no evidence of distant
metastases or evidence of local progression underwent thora-
cotomy for resection of the primary tumor. Patients found to
have progressive disease went off study but continued on fol-
low-up. Response determinations were required at this point
in the study. A complete response was complete radiologic
disappearance of all measurable or evaluable disease. A par-
tial response was a 50% or greater decrease under baseline in
the sum of products of perpendicular diameter of all measur-
able lesions. Progression was a 25% or greater increase in the
sum of products of all measurable lesions. Stable disease was
lesions that did not meet the criteria for complete response,
partial response, or progression.
Thoracotomy was performed 3 to 5 weeks after the com-
pletion of induction chemoradiation. A lobectomy or pneu-
monectomy was required for resection, and lesser pulmonary
resections were not allowed. Areas of direct tumor extension
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into the chest wall or spine were resected en bloc with the
involved lung. Coverage of the bronchial stump with a mus-
cle flap was not mandated. Thoracic surgeons were strongly
encouraged to seek neurosurgical consultation preoperatively
to assist in the spine resection if necessary. All visible and
technically accessible bronchopulmonary, hilar, and medi-
astinal lymph nodes were to be removed and submitted
appropriately labeled to the pathologist. For right-sided
tumors, these included lymph nodes at levels 2R, 4R, 7, 8, 9,
and 10R. For left-sided tumors, these included lymph nodes
at levels 5, 6, 7, 8, 9, and 10L. No intraoperative radiation or
brachytherapy was given.
Boost chemotherapy and follow-up. All patients, whether
they had a complete or incomplete tumor resection or did not
undergo a thoracotomy because they refused or were medically
unfit for surgery, were to receive 2 additional cycles of
chemotherapy identical to what was administered during the
induction regimen but without any further radiation. On com-
pletion of all treatment, all patients were followed up. Patients
were evaluated every 3 months during the first 2 years postop-
eratively and then every 6 months thereafter by history, physi-
cal examination, chest radiography, and blood tests. In addition,
scans of the brain, chest, and upper part of the abdomen were
required every 6 months for the first 3 years postoperatively.
After that time, they were done only if clinically indicated.
Study coordinator and statistical analyses. All of the
data forms, chemotherapy flow sheets, radiology reports
including CT and MR imaging reports, operative sum-
maries, and pathology reports were reviewed independently
and jointly by the study chair (V.R.) and the medical oncol-
ogy coordinator for this trial (M.K.) and either confirmed
or, if incorrect, amended. In addition to the usual quality
control performed by study coordinators, particular atten-
tion was given to ensuring that the initial tumor stage,
response to treatment, type and extent of resection, and final
pathologic stage were correctly coded. Particular attention
was given to verifying the pretreatment T status, making
certain that tumors were coded as T4 only if imaging stud-
ies clearly documented spine invasion or encasement of the
subclavian vessels.
Survival was estimated by the product-limit method,20 and
curves were compared via log-rank tests. Potential prognos-
tic factors were assessed for their significance in predicting
survival via Cox regression analysis.21 Groups of continuous
data were compared by the Wilcoxon rank-sum test. All data
were analyzed with Statistical Analysis Software, version
6.12 (SAS Institute, Inc, Cary, NC). All reported significance
values were 2-tailed.
Results
Demographic information. From April 15, 1995, to
August 1, 1999, 116 patients entered the study. Broad
participation from all of the North American coopera-
tive groups allowed this study to be completed in a
timely manner. The cooperative groups entering
patients included the Eastern Cooperative Oncology
Group (ECOG, 33 patients), the Cancer and Leukemia
Group B (CALGB, 29 patients), the National Cancer
Institute of Canada (NCIC, 26 patients), SWOG (19
patients), and the North Central Cancer Treatment
Group (NCCTG, 9 patients). Of these 116 patients, 111
were ultimately deemed eligible. The reasons for ineli-
gibility included metastatic disease in 4 patients and
postobstructive pneumonia in 1 patient, who was taken
off study before receiving induction therapy. Although
93 (84%) patients were cared for in academic institu-
tions, 16% were treated in community hospitals.
Seventy-six surgeons operated on the patients entered
in this trial, with the mean number of patients per sur-
geon being 1.42. 
The prestudy characteristics of the 111 eligible
patients are outlined in Table I. The majority of patients
were male (69.4%) and white (88%) and had T3 pri-
mary tumors (72.1%). Most patients had a performance
status of 1 (72.1%), consistent with the fact that most
patients have significant symptoms at presentation, and
most had 5% or less weight loss. The median patient
age was 56 years (range 36-77 years). The primary
tumors were generally large at diagnosis, and the medi-
an tumor size was 6 cm (range 2-14.5 cm).
Induction therapy. The protocol schema and the
numbers of patients treated at key points in the study are
shown in Fig 1. Complete documentation of induction
therapy is available for 109 of the 111 patients, 2 patients
having been lost to follow-up. Seven of these did not
complete induction as planned. There were 3 (2.7%)
treatment-related deaths during induction therapy, which
were related to neutropenic sepsis in 1 patient and to
myocardial infarction in 2 patients. Progressive disease
developed in 1 patient, and another patient received only
1 cycle of chemotherapy preoperatively because of the
development of a lung abscess. The remaining 2 patients
underwent surgery but the details of their induction ther-
apy have not yet been received.
Ten patients were taken off study because of progres-
sive disease found at postinduction restaging. Eighty-
seven of the 95 patients potentially eligible for thora-
cotomy (ie, alive and progression-free, known to have
completed induction without being taken off study)
were registered to the surgery step of the protocol. Four
patients were deemed not to have technically resectable
tumors by the surgeon. Four patients were taken off
study at the discretion of the investigators because of
excessive delay in going to surgery, poor performance
status, or poor cardiopulmonary function. Four patients
were registered to surgery but have no documentation
that surgery was actually performed. Therefore, 83
(75%) of the 111 eligible patients underwent surgery.
The most common toxicities of the induction treat-
ment according to grade are shown in Table II.
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Leukopenia, neutropenia, and anemia were the most
common grade 3 or higher toxicities. Five patients had
grade 3 or higher toxicity from esophagitis. Overall, the
induction therapy was well tolerated. Eighteen patients
had a deterioration in their performance status with
induction therapy. There were no complete radiologic
responses among the 109 patients known to have
received induction therapy. Thirty-nine (36%) of these
patients had a partial response and 45 (41%) were
judged to have stable disease.
Data on preoperative and postoperative pulmonary
function were available in 108 patients. Changes in
pulmonary function were assessed by examining the
difference between the percent of predicted values for
FEV1 (forced expiratory volume in 1 second) and for
the DLCO (diffusion capacity). The median changes in
Fig 1. Schema of SWOG 9416, also showing the number of patients treated at each of the major steps of the
study.
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percent predicted FEV1 and DLCO were +2.0% and
–7.0%, respectively.
Surgery. Data on the operations performed are sum-
marized in Table III. As might be expected for NSCLC
in this location, the most frequent operation was a
lobectomy and chest wall resection. The 12 patients
who had only a pulmonary resection all had such
marked tumor regression after the induction therapy
that chest wall resection was no longer considered nec-
essary. The data forms for this study did not allow for
more detailed coding of complex procedures such as
vertebral body resection and reconstruction, and the
small number of patients undergoing such additional
procedures are listed in Table III under “other.” The
resections were surgically complete (R0 or R1 resec-
tion) in 55 (92%) of the 60 patients with T3 tumors and
21 (91%) of the 23 patients with T4 tumors. Similarly,
92% of the patients T3 disease and 87% of those with
T4 disease had resections that proved to be pathologi-
cally complete (R0 resection).
The median duration of the operation was 4.48 hours
(range 0.85-9.32 hours) and the median estimated
blood loss was 450 mL (range 10-2100 mL).
Postoperative complications are listed in Table IV. Two
patients (2.4%) died postoperatively. These 2 patients
had postoperative respiratory failure and eventual mul-
tisystem failure. The most common complications were
pulmonary, specifically atelectasis and pneumonia,
occurring in 14.5% and 12.0% of patients, respectively.
There were several other major but infrequent compli-
cations including atrial or ventricular arrhythmias,
myocardial infarction, bronchopleural fistula, hemor-
rhage necessitating reoperation, and empyema. The
median length of hospital stay was 7 days (range 3-64
days). With the use of the Wilcoxon rank-sum test, the
occurrence of postoperative complications was exam-
ined in relation to the changes in pulmonary function as
noted previously, specifically, the difference in percent
of predicted values for FEV1 and DLCO before and
after induction therapy. There were no significant dif-
ferences in FEV1 changes (P = .77) or in DLCO
changes (P = .83) between patients with no complica-
tions versus those who had at least 1 postoperative
complication.
Review of the postinduction therapy CT scan reports
and of the pathology reports from the pulmonary resec-
tions suggested that many patients had a large residual
Table I. Prestudy characteristics of all eligible
patients (N = 111)
Prestudy characteristic No. of patients Percent of all patients
Sex
Male 77 69.4
Female 34 30.6
Ethnicity
White (non-Hispanic) 98 88
Black (non-Hispanic) 9 8
Asian or Pacific Islander 1 1
Native American 1 1
Other 2 2
T status
T3 80 72.1
T4 31 27.9
Performance status
No data 1 0.9
0 28 25.2
1 80 72.1
2 2 19.8
Weight loss
No data 7 6.3
≤5% 82 73.9
>5% 22 19.8
Table II. The most common toxicities of induction
therapy (N = 106) 
Grade
Toxicity type ≤ 2 3 4 5
Leukopenia 66 29 11 0
Neutropenia 65 25 16 0
Anemia 89 14 3 0
Esophagitis 103 3 0 0
Mucositis 104 2 0 0
Nausea 99 7 0 0
Vomiting 98 7 1 0
Fatigue/malaise 98 8 0 0
The numbers of patients are listed by grade of each form of toxicity.
Table III. Data on surgical resections performed on
patients entered in SWOG 9416 (N = 83)
No. of Percent of 
Study characteristic patients all patients
Operation type
Exploratory thoracotomy 2 2.4
Lobectomy 11 13.3
Lobectomy + chest wall 56 67.5
Pneumonectomy 1 1.2
Pneumonectomy + chest wall 2 2.4
Other 11 13.2
Completeness of resection
Surgically complete (R0, R1) 76 91.6
T3 55/60 92.0
T4 21/23 91.0
Pathologically complete (R0) 75 90.4
T3 55/60 91.3
T4 20/23 87.0
was relatively small, there was no significant difference
in survival between patients with T3 and those with T4
tumors, calculated either for all eligible patients (P =
.65) or for patients undergoing resection (P = .33). The
overall postoperative survival of patients by pathologic
response is shown in Fig 5. The median survival for
each of these 3 groups has not yet been reached. The
survival parallels the pathologic response, with the
patients who had a pathologic complete response hav-
ing the best survival and those who had gross residual
disease faring the worst. However, these apparent dif-
ferences are not statistically significant (P = .49).
To guard against the detection of what are more like-
ly to be spurious associations, we first assessed the
potential prognostic factors for their significance in
predicting survival by using a univariate Cox regres-
sion analysis. Those factors found to be significant in
the univariate setting would have been further evaluat-
ed in a model with multiple covariates. In this study,
potential prognostic factors included initial T status
(T3 vs T4), sex (male vs female), and pathologic
response (pathologic complete response vs microscop-
ic residual disease vs gross residual disease). None of
these factors was found to be significant at the .05 level
in univariate analyses of survival; therefore, multivari-
ate Cox regression analysis was not indicated. The
association between these factors and overall survival
is further defined in Table VI, which shows the relative
risks of death after surgery according to T status,
pathologic response, and patient sex.
Information about the first postoperative site of
relapse has been received on 39 patients at the time of
this analysis, including 29 patients who originally had
T3 and 10 patients who were considered to have T4
tumors at study entry. The most common single site of
relapse was the brain, with recurrence confined to this
site in 16 (41%) of the 39 patients. Local recurrence
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mass on CT but only a few scattered foci of tumor with-
in mostly residual fibrosis at operation. Therefore, the
final pathologic response was divided into 3 categories:
pathologic complete response (no residual microscopic
tumor), minimal microscopic residual (few scattered
tumor foci within mostly necrotic or fibrotic mass), and
gross residual disease (mostly or entirely viable tumor).
Each of these categories was found to include roughly
one third of the resected specimens, which meant that
65% of patients had either a complete pathologic
response or minimal microscopic residual tumor. Table
V illustrates the correlation between radiologic and
pathologic responses and shows a substantial discrep-
ancy between them. Of the 38 patients considered to
have a radiologic partial response, 28 (73%) proved to
have a pathologic complete response or minimal micro-
scopic residual disease. Even more important, of the 40
patients deemed to have stable disease, 22 (55%) were
found to have either a pathologic complete response or
minimal microscopic residual disease.
Boost chemotherapy. Fifty-nine patients were regis-
tered to boost chemotherapy, including 58 who had
surgery and 1 who did not. Among the 29 patients who
were registered to surgery but not to boost chemother-
apy, the reasons for not registering to boost chemother-
apy, in addition to the 2 postoperative deaths, were as
follows: disease progression detected after surgery (3
patients), inadequate postoperative recovery or patient
fragility precluding further chemotherapy (11 patients),
change in histologic diagnosis after tumor resection (2
patients), patient refusal (4 patients), and other reasons
or no reason given (7 patients). For the patients regis-
tered to boost chemotherapy, 47 patients (81% of
patients registered to this step, 42% of all eligible
patients entered on study) actually received the 2 cycles
of chemotherapy planned, and an additional 6 patients
received 1 cycle of chemotherapy.
Survival and relapse information. As of March 28,
2000, 72 of the 111 eligible patients are still alive. One
patient has no follow-up beyond the date of registration
and is excluded from the survival analysis. The median
follow-up among the 72 patients still living is 21
months. The overall survival for all eligible patients
and the postoperative survival for the patients who had
a complete resection are shown in Figs 2 and 3. The
median survival for both groups of patients has not yet
been reached. The overall survival for all eligible
patients appears to reach a plateau of approximately
55% at 2 years after initial chemotherapy; for the
patients who had a complete resection, the plateau was
approximately 70% at 2 years postoperatively.
The overall survival by initial T status is shown in Fig
4. Although the total number of patients with T4 tumors
Table IV. Postoperative complications in SWOG 9416
Complication type No. of patients Percent of patients
Atelectasis 12 14.5
Pneumonia 10 12.0
Atrial arrhythmia 9 10.8
Empyema 4 4.8
Hemorrhage, reoperation 2 2.4
Myocardial infarction 2 2.4
Bronchopleural fistula 2 2.4
Ventricular arrhythmia 2 2.4
Wound infection 1 1.2
Of the 83 patients who underwent thoracotomy, 14 (17.5%) had no complica-
tions reported. In 3 patients no information was submitted about complica-
tions. Some patients had more than 1 complication.
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only was uncommon, occurring in 9 (23%) patients.
Including brain relapses, the most frequent form of
recurrence was distant only (26/39 or 66%). The num-
bers of recurrences are too small to allow comparisons
between T3 and T4 tumors or according to the degree
of pathologic response.
Discussion
Preoperative radiation and surgical resection became
the standard management of NSCLC of the superior
sulcus after Shaw and associates1 described this in
1961. The feasibility of this approach has been con-
firmed by multiple surgical series that have reported a
relatively consistent overall survival of approximately
30% at 5 years.5,7,9-12,14,16,22-25 Radiation alone has
been associated with a 5-year actuarial survival of
23%,8,26 but these results probably cannot be compared
with those of surgical series because of variability in
patient selection. Recent surgical series have focused
on exploring the use of extended operations to achieve
complete resection of T4 tumors that invade the sub-
clavian vessels or spine and on defining prognostic fac-
tors. The development of the anterior transcervical
approach by Dartevelle,12 Macchiarini,27 and their col-
leagues now allows complete resection of anteriorly
located tumors involving the subclavian vessels, which
were previously considered unresectable. Likewise, the
thoracic and neurosurgical groups at the Memorial
Sloan-Kettering and MD Anderson Cancer Centers
have highlighted the benefit of a multidisciplinary
approach to posteriorly located tumors that can only be
removed by formal spine resection and stabiliza-
tion.28,29 Although both of these experiences represent
important contributions to the surgical management of
NSCLC of the superior sulcus, the overall survival and
rates of complete resection of these patients remain rel-
atively low.
A recent review of 225 patients operated on
between 1974 and 1998 at Memorial Sloan-Kettering
Cancer Center summarizes important aspects of the
traditional surgical management of superior sulcus
tumors and clearly defines prognostic factors that
have been suggested by previous series.17,30 This
experience confirms that surgical resection can be
accomplished with a low mortality (4%) but empha-
sizes that complete resection (R0 resection) was
achieved in only 64% of T3 N0 and 39% of T4 N0
tumors. The actuarial 5-year survival was 46% for
stage IIB (T3 N0) and 13% for stage IIIB disease,
most of which were T4 N0 tumors. By univariate and
multivariable analyses, T and N status and complete
resection had a significant impact on survival.
Locoregional recurrence was the most common form
of relapse, occurring in 40% of patients. Within this
large series, the more recent experience encompass-
ing the years of 1992 to 1998 did not differ substan-
tially from the earlier reported experience covering
the years 1974 through 1991. However, the negative
prognostic impact of N2 disease, the inadequacy of
limited pulmonary resection in these patients, and the
lack of benefit of brachytherapy in incomplete resec-
tions have now been recognized.13,17
Table V. Comparison of pathologic and radiologic responses in the 83 patients entered in SWOG 9416 who 
underwent thoracotomy
Radiologic response
Total PR PRNM STA NASS
Pathologic stage
Pathologic CR 28 14 0 12 2
Minimal microscopic residual disease 26 13 1 10 2
Gross residual disease 29 10 0 18 1
Total 83 37 1 40 5
PR, Partial response; PRNM, partial response, evaluable not measurable; STA, stable; NASS, not assessable.
Table VI.  SWOG 9416 relative risk of death after surgery
Prognostic factors RR 95% CI P value
T3 vs T4 1.61 0.69-3.71 .27
Microscopic residual disease vs CR* 1.60 0.56-4.63 .38
Gross residual disease vs CR 1.86 0.66-5.24 .24
Men vs women 1.93 0.71-5.20 .20
RR, Risk ratio; CI, confidence interval; CR, complete response.
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The Memorial Sloan-Kettering series and others
emphasize the need for improved treatment of supe-
rior sulcus tumors, especially with respect to achiev-
ing complete resection and, by extension, long-term
local control. The success of induction chemotherapy
and chemoradiation in the treatment of stage IIIa
(N2) NSCLC has prompted interest in applying this
approach to superior sulcus tumors.31 A small phase
II trial reported by Martínez-Monge and coworkers15
suggested that induction chemotherapy and radiation
might lead to improved results. From 1988 to 1992,
18 patients with either T3 or T4 NSCLC of the supe-
rior sulcus were treated with induction chemotherapy
(mitomycin, vindesine, and cisplatin or carboplatin)
for 1 to 3 cycles followed by combined chemothera-
py and radiation (total doses of 46 to 50 Gy) and then
surgical resection. Although the induction therapy
was not uniform across the entire group of patients,
the resectability rate was 76.4%, the complete patho-
logic response rate was 70.5%, and the actuarial 4-
year survival was 56.2%. These encouraging results
indicate that further study of a combined modality
approach is warranted. However, the high rate of
treatment-related death (16.6%) mandates use of a
different induction regimen.15
The use of combined chemotherapy and radiation is
particularly attractive for the treatment of T3 and T4
superior sulcus tumors, especially if patients with N2
disease are excluded. This strategy exploits the synergy
of concurrent therapy to treat tumors that present first
and foremost a major problem in local control. The reg-
imen used in this trial was extensively tested in previ-
ous trials conducted by SWOG, particularly in stages
IIIa (N2) and selected stage IIIb NSCLC, and found to
Fig 2. Overall survival of all eligible patients with follow-up.
Fig 3. Overall survival after surgery for eligible patients with complete resections.
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be feasible and effective in the multi-institutional set-
ting.18,19 Thus, there was a strong rationale for testing
the same induction regimen in superior sulcus tumors.
The results of this trial, with an overall treatment-
related mortality of only 4.5%, show that induction cis-
platin and etoposide with concurrent radiation followed
by surgical resection is a feasible and well-tolerated
regimen even when used across a broad range of insti-
tutions and surgeons, including community hospitals.
The rates of pathologic response, complete resection,
and overall survival appear to be significantly better
than in past surgical experience. This is particularly
true of patients with T4 tumors and suggests that a
combined modality approach provides a far more
favorable outcome for these tumors, which have usual-
ly been considered unresectable and incurable. The
effectiveness of this regimen is also notable given the
large size of most of the tumors at diagnosis, a situation
in which radiation alone has limited impact.
This study highlights several other important find-
ings. The discrepancy between radiologic and patho-
logic response after combined chemotherapy and radi-
ation was noted in the previous SWOG trial with this
regimen18 but is particularly striking here. Only 40%
of the patients with radiologically stable disease and
27% of the patients with a radiologic partial response
actually had significant gross residual tumor at thora-
cotomy. This finding underscores the importance of
not using radiologic response as a criterion for resec-
tion in this setting. Another important finding is that a
relatively small proportion of patients were able to
receive postoperative boost chemotherapy as planned.
This reconfirms the experience of virtually all previ-
ous adjuvant chemotherapy trials.32 Most patients with
lung cancer recovering from a major operation tolerate
postoperative chemotherapy poorly. 
This treatment regimen also appears to have changed
the patterns of relapse from predominantly local to
Fig 4. Overall survival by stage for all eligible patients with follow-up.
Fig 5. Overall survival after surgery by pathologic response.
mostly distant.14,17,23,30 The high frequency of relapse
in the brain has been observed in other reports of supe-
rior sulcus tumors26,30 and raises the complex question
of whether patients who have a better prognosis (ie,
major or complete pathologic response and complete
resection) should be offered prophylactic cranial radia-
tion. An identical problem has been observed in the
patients who receive combined modality therapy for
stage IIIa (N2) NSCLC.18
To our knowledge, this is the first prospective
multi-institutional trial in NSCLC of the superior sul-
cus. Although a phase II trial, this study effectively
sets a new standard of care by virtue of the substan-
tially better outcome achieved compared with recent
surgical series reporting the results of radiation and
resection without chemotherapy. Unfortunately, the
large number of institutions and of surgeons across
North America required to complete this trial over a
5-year period attests to the rarity of this subset of
NSCLC and indicates that it is unlikely that a phase
III trial confirming the superiority of this approach
could be performed in a timely manner. Therefore,
future trials, also of phase II design, will have to
address the areas where this regimen appears to have
failed.
The combination of cisplatin and etoposide is
widely considered an “old fashioned” chemotherapy
regimen and has been discarded by many oncolo-
gists in favor of more recently developed agents
including carboplatin, paclitaxel, vinorelbine, and
gemcitabine. However, the superiority of these
agents in combination with radiation as an induction
regimen remains unproven. The low toxicity and
high response rates seen with etoposide, cisplatin,
and radiation in this study emphasize that this
approach remains a highly effective, well-tolerated,
and therefore standard regimen in the multi-institu-
tional setting. Future trials should probably not seek
to alter this particular chemotherapy and radiation
combination, but instead add to it to diminish the
risk of systemic relapse. Possible approaches
include the addition of a chemotherapy agent such
as docetaxel, which appears to be effective even in
tumors previously treated with or resistant to cis-
platin,33 or biologic agents such as antiangiogenesis
agents or tyrosine kinase inhibitors, which may
enhance the response to chemotherapy or decrease
the risk of systemic relapse. The design of a new
trial that will build on the results presented here is
currently under discussion. In the interim, the initial
results of intergroup 0160 offer improved treatment
for patients with T3 and T4 N0-1 NSCLC of the
superior sulcus.
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difficult tumor. It is important to emphasize the historical per-
spective that Dr Rusch alluded to. 
Just over 40 years ago this tumor was thought to be incur-
able. Then Dr Paulson (the 61st president of our Association)
and his colleagues presented their work using preoperative
radiotherapy and en bloc resection, achieving a 30% to 35%
cure rate. As Dr Rusch mentioned, this has been the standard
of care for all of these years. 
We at the Massachusetts General Hospital had followed Dr
Paulson’s lead and achieved similar results, with a cure rate
of about 30% and a local recurrence rate of about 30%. About
4 years ago we also instituted within our own institution a
trial similar to the one presented today, using a slightly high-
er dose of radiotherapy but achieving very similar results: a
94% complete resection rate, an 87% 4-year actuarial sur-
vival, and no local recurrences to date. We would applaud the
results that you have achieved, Dr Rusch. They are very sim-
ilar to our results, and we are excited about this development. 
I have 3 questions. You mentioned the issue of brain metas-
tases. Was this figure higher than you anticipated compared
with historical controls? You alluded to the complete
response rate, but were you able to draw any conclusions rel-
ative to brain metastases between histology and complete
response rate, which might be important in determining who
would benefit from prophylactic cranial irradiation? 
Second, I was very impressed with the results in the T4
group. Could you elaborate about the extent of initial involve-
ment to provide some guidelines in that area? Were there any
operative details that would be important to share with the
audience? 
Third, are there currently any contraindications to this
approach using preoperative chemoradiotherapy for Pancoast
tumors, and does it now have some role to play in patients
with N2 disease in superior sulcus tumors who were previ-
ously thought to be incurable? 
I am certain that in years to come this paper will be con-
sidered a milestone in the treatment of this tumor, much as Dr
Paulson’s paper is.
Dr Rusch. Thank you, Dr Mathisen. With respect to brain
metastases, the pattern of relapse that I have shown here is
analogous to the pattern of relapse that has been seen in vir-
tually every neoadjuvant and adjuvant trial in resectable
NSCLC and, indeed, is very much the pattern of relapse that
is seen in patients who are treated solely with surgical resec-
tion without chemotherapy. 
Many years ago, the Lung Cancer Study Group tried to
assess whether it would be feasible to do a randomized trial
testing the use of prophylactic cranial irradiation in patients
who had undergone resection for NSCLC. That paper was pub-
lished in The New England Journal of Medicine, with Dr
Robert Figlin as the first author. Basically, we found that such
a trial would be statistically impossible, because the sample
size required would be too large. At some point in the next 5 or
10 years we may need to grapple with this issue at an interna-
tional level, because clearly brain metastases are a major prob-
lem. We need to examine whether an approach similar to what
has been done in limited staged small cell lung cancer would
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Discussion
Dr Douglas J. Mathisen (Boston, Mass). I congratulate Dr
Rusch and her colleagues on this very important work. It rep-
resents the first major step forward in the treatment of this
patients who had tumors invading the spine. I see this as a
major step forward for that tumor subset. 
I can identify no particular contraindications with respect
to the use of this induction regimen, aside from the usual con-
siderations of using platinum-based treatment in patients for
induction therapy, that is, adequate renal, neurologic, and car-
diopulmonary function. 
Finally, you asked about the use of this approach in patients
with N2 disease. It is certainly to be considered. As you
know, we have used a similar regimen and have reported that,
again, in the SWOG trial several years ago, for patients who
have stage IIIa N2 disease, with excellent results. 
We are hoping to extend these results by increasing the
amount of chemotherapy, adding docetaxel to the induction
regimen. This approach may be particularly appropriate for
patients who have Pancoast tumors with N2 disease.
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be appropriate, that is, the use of prophylactic cranial irradia-
tion in patients who have successfully completed management
of the local problem and appear to be disease-free in the chest. 
With respect to the correlation of histology versus brain
metastases, we have not yet done that analysis, but that will
be appropriate as we obtain further follow-up. In fact, we are
planning to re-analyze this study for long-term results in
approximately 2 years, so we will bear that issue in mind. 
I do not have any guidelines for the management of T4
tumors. We included those tumors but stratified them specifi-
cally in this study, because we wanted to learn whether there
was any potential role for combined modality treatment of
those tumors. These patients have done surprisingly well. I
have reviewed all of the CT reports and operative reports, so
I do believe that the patients who are listed here as having T4
tumors truly have T4 tumors. They are predominantly
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